Carregando...
Differential Healing After Sirolimus, Paclitaxel and Bare Metal Stent Placement in Combination with PPARγ Agonists: Requirement for mTOR/Akt2 in PPARγ Activation
RATIONALE: Sirolimus- (SES) and paclitaxel-eluting coronary stents (PES) are used to reduce restenosis, but have different sites of action. The molecular targets of sirolimus (SRL) overlap with those of the PPARγ agonist, rosiglitazone (RSG), but the consequence of this interaction on endothelializa...
Na minha lista:
| Publicado no: | Circ Res |
|---|---|
| Principais autores: | , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4492118/ https://ncbi.nlm.nih.gov/pubmed/19797172 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCRESAHA.109.200519 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|